Navisha Dookie

Accomplished Medical Research Scientist with a PhD in Medical Microbiology and 10 years of experience in scientific research. Currently serving as Clinical Lead at IQVIA, adept at managing large-scale, multi-country clinical trials from inception to execution. Demonstrates expertise in study operations optimization, regulatory compliance, and risk management, with a proven track record in site selection and patient recruitment. Recognized for strong stakeholder engagement and strategic problem-solving abilities, complemented by extensive scientific writing experience and numerous first-author publications.

• Supervision of Research Masters Students, University of KwaZulu-Natal, Nelson R Mandela School of Medicine, 01/2019, Present, Ms P Dudhraj, dudhrajhp@ukzn.ac.za
• Supervision of Research Honours Students, University of KwaZulu-Natal, Nelson R Mandela School of Medicine, 01/2018, 12/2018, Professor M Pillay, pillayc@ukzn.ac.za

• Belinda Seager, Associate Director, Clinical Leads, IQVIA: belinda.seager@iqvia.com +27 79 513 6949
• Vesna Petrovic Patildzanovic, Director, Clinical Leads. IQVIA. vesna.petrovicpatlidzanovic@iqvia.com. +381/62/640049
• Prof Nesri Padayatchi, Deputy Director CAPRISA (Former), 0823725551, nesri.padayatchi@caprisa.org
• Prof Kogie Naidoo, Deputy Director & Head of the CAPRISA Treatment Program, 0832691756, kogie.naidoo@caprisa.org

• 49th Union World Conference on Lung Health, The Hague, Netherlands, 2019, Oral Presentation
• 8th South African AIDS Conference, Durban, South Africa, 2017, Oral Presentation
• UKZN College of Health Sciences Research Symposium, 2013, Oral Presentation
• 3rd South African TB Conference, 2012, Oral Presentation
• 4th Federation of Infectious Diseases Society of Southern Africa Congress, Durban, South Africa, 2011, Poster Presentation
• 3RD International Conference on Drug Discovery and Therapeutics, Dubai, United Arab Emirates, 2011, Poster Presentation

• Thuthuka Research Grant, 2020, National Research Foundation of South Africa
• Career Development Award, 2019, European and Developing Countries Clinical Trials Partnership (EDCTP)
• Connect Africa Travel Award, 2018
• Whitehead Scientific Travel Award, 2018
• Golden Key International Honour Society, 2017
• Scarce Skills Post-Doctoral Fellowship, 2016, National Research Foundation of South Africa
• College of Health Science Doctoral Fellowship, 2013, University of KwaZulu-Natal
• Innovation PhD Scholarship, 2012, National Research Foundation of South Africa
• Best Abstract Award, 2011, Federation of Infectious Diseases Society of Southern Africa (4th Congress - Durban, South Africa)
• Innovation Masters Scholarship, 2010, National Research Foundation of South Africa
• Honours Scholarship, 2009, University of KwaZulu-Natal

1. Perumal R, Khan A, Naidoo K, Ngema SL, Nandlal L, Padayatchi N, Dookie N. Mycobacterium tuberculosis Intra-Host Evolution Among Drug-Resistant Tuberculosis Patients Failing Treatment.Infect Drug Resist. 2023 May 9:16:2849-2859. doi: 10.2147/IDR.S408976. eCollection 2023.

2. Ngema SL, Dookie N, Permumal R, et al. Isoniazid resistance-conferring mutations are associated with highly variable phenotypic resistance. J Clin Tuberc Other Mycobact Dis.2023.

3. Naidoo K & Dookie N, Can the GeneXpert MTB/XDR deliver on its promise of Expanded, Near-Patient TB Drug-Susceptibility Testing? 2021, Lancet Inf Dis, 2022.

4. Tuberculosis Elimination in the Era of COVID-19: A Moving Target, Dookie N, Padayatchi N & Naidoo K, 2020, Clinical Infectious Diseases

5. Individualised treatment of Multi-Drug Resistant Tuberculosis using whole genome sequencing and expanded drug susceptibility testing, Dookie N, Padayatchi N, Lesseks RJ, Naicker CL, Chotoo S & Naidoo K, 2020, Clinical Infectious Diseases

6. Resistance profile of Neisseria gonorrhoeae in KwaZulu-Natal, South Africa questioning the effect of the currently advocated dual therapy, Rambaran S, Naidoo K, Dookie N, Moodley P & Sturm AW, 2019, Journal of Sexually Transmitted Diseases

7. Recurrent tuberculosis among HIV co-infected patients: A Case Series from KwaZulu-Natal, Naidoo K, Dookie N, Naidoo K, Bhushan A, Govender D, Gengiah S & Padayatchi N, 2018, Journal of Infection & Drug Resistance

8. Insights into Recurrent Tuberculosis: Relapse Versus Reinfection and Related Risk Factors, Naidoo K & Dookie N, 2018, In-Tech Open

9. Evolution of Drug Resistance in Mycobacterium tuberculosis: A Review on the Molecular Determinants of Resistance and Implications for Personalised Care., Dookie N, Rambaran S, Padayatchi N, Mahomed S & Naidoo K, 2018, Journal of Antimicrobial Chemotherapy

10. Whole genome sequencing for the management of drug-resistant TB in low income high TB burden settings: Challenges and implications, Mahomed S, Naidoo K, Dookie N & Padayatchi N, 2017, Journal of Tuberculosis

11. Mechanisms of first-line antimicrobial resistance in multi-drug and extensively drug resistant strains of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa, Dookie N, Sturm AW & Moodley P, 2016, BMC Infectious Diseases

12. Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis, Dookie N, Sturm AW & Moodley P, 2014, Journal of Infection & Drug Resistance